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A B S T R A C T  
Objective: To determine the steroid responsiveness within 8 weeks of the initial treatment of childhood nephrotic 
syndrome.  
Patients and Methods: This prospective study was conducted in Children Hospital, Pakistan Institute of Medical 
Sciences, Islamabad from January 2012 to June 2012. A total of 139 children aged 1 to 10 years of both genders 
diagnosed as nephrotic syndrome were included in the study. Those children who were already taking any form of 
therapy for Nephrotic syndrome were excluded from the study. These children were given prednisolone 60 mg/m2 of 
body surface area, divided into 3 doses for a period of 8 weeks and then switched over to 40 mg/m2 as a single morning 
dose on alternate days, in those children who showed a response. The primary outcome of the study was to see the 
response of steroid therapy at different occasions for up to 8 weeks. SPSS version 11.0 was used for data analysis. 
Mean and standard deviation were calculated for numerical variables and frequency and percentages were calculated 
for categorical variables.  
Results: In this study 16.5% of cases responded to steroids within 2 weeks, major bulk of patients (43.5%) showed 
response between 3-4 weeks, (20.1%) and (2.1%) patients responded between 5-6 weeks and 7-8 weeks respectively. 
Steroid resistant nephrotic syndrome was seen in 16% of the study cases.  
Conclusion: Steroids are first line treatment for the idiopathic nephrotic syndrome. The majority of the patients show a 
response within 8 weeks of their first presentation. Maximum number responds between 3-4 weeks.  
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I n t r o d u c t i o n  
 
Nephrotic syndrome (NS) is characterized by heavy 
proteinuria (>40 mg/m2/hr), hypoalbuminemia (<2.5 
gm/dL), oedema and hypercholesterolemia (>200 mg/dL). 
It is a very common glomerular disorder in developing 
countries including Pakistan and has significant morbidity 
and mortality due to various complications. The majority 
of children with NS show a good response to steroids 
within 8 weeks of their first presentation. NS is a common 
glomerular disorder and 15 times more common in 
children than adults.1 Estimates of annual incidence 
ranges from 2 to 7 new cases in children under 16 years 
per 100,000 population.2 The general consensus for the 
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treatment at first presentation is daily induction therapy of 
prednisolone at 60 mg/m2 given in 3 divided doses for 6 
weeks, followed by alternate day maintenance therapy of 
40 mg/m2 given as single morning dose for 6 weeks.3 
Studies found that the longer duration of corticosteroids 
lasting 12-16 weeks for the initial episode results in higher 
remission rates, longer duration of remissions and lower 
rate of subsequent relapses.4-6 Thus more aggressive 
treatment of idiopathic nephrotic syndrome with a longer 
initial course of corticosteroids (12-16 weeks) may 
improve the steroid responsiveness and consequently 
decrease the population of patients labeled as having a 
steroid-resistant nephrotic syndrome (SRNS) which is 
defined as failure to achieve remission on completion of 8 
weeks of full dose daily steroids.  
Steroid responsiveness in childhood idiopathic nephrotic 
syndrome (INS) have been found consistent,1,7 however, 
in some studies variability has also been reported. 
Numerous reports have shown wide racial and 
geographical variation in the presentation of INS and 
response to therapy.8-10 Minimal change disease (MCN) is 
the most common histopathological lesion (85%) and 
generally has a favorable response to steroids therapy in 
85-90% of the patients1,7,11-13 This is followed by focal 
segmental glomerulosclerosis (FSGS) 10% and 
mesengial proliferation (5%), which shows less (approx. 
<20%) response to steroids. Approximately 50% of 
patients with diffuse early membranoproliferative 
glomerulonephritis (MPGN) show an early response to 
steroid and undergo complete remission. An additional 
20% have continued proteinuria and 6% progress to renal 
insufficiency and chronic renal failure.14 
The present study was planned to estimate the efficacy of 
steroid responsiveness in childhood nephrotic syndrome 
within 8 weeks of the first presentation in order to develop 
strategies to reduce the complications of INS which prove 
to be fatal in children.  
    P a t i e n t s  a n d  M e t h o d s  
This prospective study was conducted at the Department 
of Pediatrics Medicine at Children’s Hospital, Pakistan 
Institute of Medical Sciences, Islamabad from January 
2012 to June 2012. A total of 139 patients, aged 1 to 10 
years of both genders, with newly diagnosed Nephrotic 
Syndrome, including those patients who were referred 
from health facilities to the Nephrology Clinic of the 
Children Hospital were included in the study. Children 
who were already taking any form of medication for NS 
were excluded from the study. Similarly, those patients 
with impaired renal function and secondary etiologies of 
NS like systemic lupus erythematosus, Hersch Scholien 
Purpura, Sickle cell anemia, malignancies, metabolic 
disorders, hepatitis and any form of renal malformations 
were excluded from the study.  
Ethical approval was taken from the ethical committee of 
PIMS Hospital. A detailed history including history of 
gross haematuria, hypertension, jaundice, joint pain, rash 
and drug intake was recorded. Patients were evaluated 
for hypertension, anthropometric parameters (height, 
weight, body surface area) and systemic involvement. 
They were investigated for confirmation of nephrotic 
syndrome and exclusion of secondary causes. After 
diagnosing NS they were started on prednisolone 60 
mg/m2 of body surface area divided into 3 doses for a 
period of 8 weeks and then switched over to 40 mg/m2 as 
a single morning dose on alternate days in those patients 
who showed a response, irrespective of underlying 
histopathology. The primary outcome of the study was to 
see the response of steroid therapy at different occasions 
up to 8 weeks. Steroid response was seen and recorded 
into groups i.e. within 2 weeks, 3-4 weeks, 5-6 weeks and 
7-8 weeks.  
SPSS versions 11.0 was used for data analysis. The 
frequency and percentage were calculated for categorical 
data (gender, steroid response). Mean and standard 
deviations were calculated for numerical data (age, 
height, weight, body surface area). 
R e s u l t s  
In this study, a total of 139 patients with nephrotic 
syndrome were enrolled. The Mean±SD age of study 
patients was 48.1 months +25.3SD, ranging from 10 to 
120 months. The majority of the children 82 (58.9%) were 
between 24 to 59 months of age. Twenty-one (15.1%) 
children were up to 24 months of age while 36 (25.9%) 
were off 60 months or above. Male gender was found in 
dominance in this study, comprising of almost 75% 
patients. The male to female ratio was 2.9 : 1 (Table 1).  
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Up to 2 weeks 3 to 4 weeks 5 to 6 weeks 7 to 8 weeks 
Table 1: Demographic characteristic of study patients  
(n = 139) 
 Number Percentage 
Age (months) 
   Up to 24 
   24 to 59 
   60 and above 
 
21 
82 
36 
 
15.1 
58.9 
25.9 
Age (months) 
Age; Mean±SD 
Range (min – max) 
 
48.1 (25.3) 
10 – 120 
 
Gender 
   Male 
   Female 
 
104 
35 
 
74.8 
25.2 
Male:Female ratio 2.9: 1  
 
The response of steroid was calculated on different 
occasions. In this study, 23 (16.5%) of newly diagnosed 
nephrotic syndrome patients responded to steroids within 
2 weeks of therapy. The response rate between 3 to 4 
weeks was even high as 63 (45.3%) of study patients 
responded in this period. Out of the total 139 patients, 28 
(20.1%) patients responded between 5 to 6 weeks of 
therapy. Similarly, 3 (2.1%) cases responded between 7 
to 8 weeks of initiation of steroid therapy. However, 22 
(16.0%) of patients showed no response to steroid even 
in 8 weeks and were labeled as steroid resistant. (Figure 
I)  
 
Time of steroid 
response 
Figure I: The trend of steroid response in the study  
(n = 139) 
 
 
 
We also analyzed the steroid response according to the 
gender of patients. Out of total 104 male patients, 20 
(19.2%) responded within 2 weeks, 50 (48.1%) responded 
between 3 to 4 weeks, 19 (18.2%) responded between 5 
to 6 weeks while 1 (0.9%) patient responded between 7 to 
8 weeks. Fourteen (13.4%) of the male patients showed 
resistance. Similarly, out of total 35 female patients, 4 
(11.4%) responded within 2 weeks, 13 (37.1%) responded 
between 3 to 4 weeks, 9 (25.7%) responded between 5 to 
6 weeks and 1 (2.8%) patient responded between 7 to 8 
weeks. Eight (22.8%) of the females were found resistant 
to steroid therapy (Table 2).  
Table 2. Steroid response according to gender. 
 Male (n = 104)  
n(%) 
Female (n = 35) 
n(%) 
Up to 2 weeks 20 (19.2) 4 (11.4) 
3 to 4 weeks 50 (48.1) 13 (37.1) 
5 to 6 weeks 19 (18.2) 9 (25.7) 
7 to 8 weeks 1 (0.9) 1 (2.8) 
Resistance to 
steroids 
14 (13.4) 8 (22.8) 
 
While analyzing steroid response according to age of the 
patients it was found out that of the total 22 patients of up 
to 24 months, 4 (18.1%) responded within 2 weeks, 11 
(50.0%) responded between 3 to 4 weeks, 3 (13.6%) 
responded between 5 to 6 weeks while 1 (4.5%) patient 
responded between 7 to 8 weeks. Three (13.6%) of the 
under 24 months’ patients showed resistance to steroid 
therapy. Similarly, out of total 82 patients between 24 and 
59 months of age, 16 (19.5%) responded within 2 weeks, 
36 (43.9%) responded between 3 to 4 weeks, 18 (21.9%) 
responded between 5 to 6 weeks and 0 (0.0%) patient 
responded between 7 to 8 weeks. Twelve (14.6%) of the 
patients were found to have resistance to steroid therapy. 
Out of 35 patients of 60 or above months of age, 4 
(11.4%) responded within 2 weeks, 16 (45.7%) responded 
between 3 to 4 weeks, 7 (20.0%) responded between 5 to 
6 weeks and 1 (2.8%) patient responded between 7 to 8 
weeks. While 7 (20.0%) of the patients were found to 
have resistance against steroid therapy in this age group. 
(Table 3) Overall out of 139 patients, 22 (16.0%) had 
steroid-resistant nephrotic syndrome (SRNS).  
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Table 3: Steroid response according to age. 
 Up to 24 
mon 
(n = 22) 
n(%) 
24-59 mon 
(n = 82) 
n(%) 
60 and 
above 
(n = 35) 
n(%) 
Up to 2 
weeks  
4 (18.2) 16 (19.5%) 4 (11.4) 
3 to 4 weeks 11 (50.1) 36 (43.9) 16 (45.7) 
5 to 6 weeks 3 (13.6) 18 (21.9) 7 (20.0) 
7 to 8 weeks 1 (4.5) 0 (0.0) 1 (2.8) 
Resistance 
to steroids 
3 (13.6) 12 (14.6) 7 (20.0) 
 
D i s c u s s i o n  
Nephrotic syndrome is the most common chronic 
glomerular disease in children. In 85% of children, there is 
minimal change disease and it generally has a favorable 
response to glucocorticoid therapy in 90% of patients.1 In 
about 40% of the steroid-sensitive nephrotic syndrome 
(SSNS), relapse may occur and some of these patients 
may become steroid dependent. Response to steroids 
also vary geographically.15-17 In few studies from the 
African region, the steroid response rate was as low as 
20% in children with Nephrotic syndrome while some 
reports showed paucity of minimal change disease and 
also poor response to steroids.15-17 In our study patients, 
demographic features are comparable to these reports 
where we found out the mean age of 4.1 years with male 
population in majority 75%. The dominance of male 
gender in our study could be due to the social norms in 
the developing world as parents and caretakers give 
priority care to boys compared to girls even for medical 
consultation.   
In a study by Safaei A and Maleknejad S on the spectrum 
of childhood Nephrotic syndrome, the mean age of 
patients was 4.8 years and the male population was 
dominant with 66% proportion.18 In another study the 
mean age of patients was 5.8 years and gender 
distribution was equal with 50% in each strata.12 In this 
study conducted for evaluation of steroid response in 
children with NS, 17% of cases responded to steroids 
within 2 weeks, 46% responded between 3 to 4 weeks 
while 22% and 9% patients responded to steroid between 
5 to 6 weeks and 7 to 8 weeks respectively. It was proven 
again that NS responds well to steroids in the pediatric 
population as more than 60% of our patients responded 
within 4 weeks of start of therapy. Steroid resistance was 
found in 16.0% of our cases. In a local study by Azam M 
and colleagues on nephrotic syndrome, the steroid 
response was reported to be 76% within 4 weeks of 
therapy, 16% responded within 8 weeks of steroid therapy 
while 6% did not responded even after 8 weeks.8 
In another study by Anochie I and colleagues on the 
pattern of steroid response in children with NS after 1 
month of therapy, more than 70% had responded well and 
57% got complete remission while 14.3% had resistance 
against steroids. Another 14.3% had frequent relapsing 
nephrotic syndrome and became steroid dependent.12 In 
a study from Iran it was reported that 66% children with 
Nephrotic syndrome were steroid sensitive, 20% were 
steroid resistant while 14% were steroid dependent.18 The 
above-mentioned steroid response rate is comparable to 
our study findings, we found out that more than 60% of 
the children responded to steroid within 4 weeks of 
therapy, 22% responded between 5 to 6 weeks while 10% 
responded between 7 to 8 weeks after start of steroid 
therapy. In our study, more than 53% of the responders 
were between 2 to 6 years of age.  These findings are 
almost similar to Anochie I’s study, where they noted that 
about 50% of cases who responded to steroid therapy 
were between 1 to 4 years.12 The steroid response 
according to the gender of patients was quite similar. Out 
of total 104 males, 18.2% responded within 2 weeks, 
48.1% responded between 3 to 4 weeks, 18.2% 
responded between 5 to 6 weeks while 0.9% responded 
between 7 to 8 weeks. Similarly, of total 35 female 
patients, 11.4% responded within 2 weeks, 37.1% 
responded between 3 to 4 weeks, 25.7% responded 
between 5 to 6 weeks and 2.8% responded between 7 to 
8 weeks.  
Overall out of 139 study patients, 22 (16.0%) had steroid-
resistant nephrotic syndrome (SRNS). In a study by 
Iyengar A and colleagues, steroid resistance was found in 
36% of under 24 months’ patients while in 46.2% patients 
above 24 months of age.19 Overall 58.3% of their study 
patients had steroid resistance, which was quite high 
compared to our study as we found steroid resistance in 
16% cases. Another study from Iran reported a similar 
(20.0%) resistance to steroids which is close to our study 
findings.18 The current study was one of the very few 
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prospective trials done in the local settings on children 
with nephrotic syndrome. The sample size was adequate 
for a reasonable study population comprising of 139 
children. One of the benefits of the study is that steroid 
response has been evaluated in almost all pediatric age 
groups from 1 year to 10 years.  
There were few limitations of the current study, as there 
was no collection of information regarding patients 
presenting complaints and etiology of the disease. A more 
dynamic approach of collection study information would 
have provided some details regarding etiology of study 
patients and understanding the pattern of steroid 
response better.  
C o n c l u s i o n  
Our study approves the scientific evidence in favor of 
steroids for children with nephrotic syndrome. Idiopathic 
nephrotic syndrome is a constant presentation in our 
setting and steroids can be a sensitive drug for its 
treatment. The majority of the patients showed a 
response within 8 weeks of their first presentation. Most of 
these patients respond to steroid therapy during 4 weeks 
of initiation of treatment. There is also a need to study 
different doses of steroids for the different duration in 
these patients to check efficacy.  
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